A Non-interventional Study to Assess the Safety and Efficacy of First Line Therapy With Vectibix® in Combination With FOLFIRI and to Validate a Prognostic Score in Adult Patients With RAS Wild-type Metastatic Colorectal Cancer in a Real World Setting (VALIDATE)
Latest Information Update: 13 Jan 2025
Price :
$35 *
At a glance
- Drugs Panitumumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms VALIDATE
- Sponsors iOMEDICO AG
- 13 Sep 2024 According to an Amgen media release, final results of the non-interventional study VALIDATE will be presented at the European Society for Medical Oncology (ESMO) Congress 2024, taking place Sept. 13-17 in Barcelona.
- 23 Apr 2024 Status changed from active, no longer recruiting to completed.
- 24 Oct 2023 Updated second interim analysis Results presented at the 48th European Society for Medical Oncology Congress